Integrated Filing — IndAS



General information about company

Scrip Code 542919
NSE Symbol ARTEMISMED
MSEI Symbol NOTLISTED
ISIN INE025R01021
Name of company ARTEMIS MEDICARE SERVICES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 30-10-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 27-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Healthcare Services
Start date and time of board meeting 30-10-2026   16:00:00
End date and time of board meeting 30-10-2026   17:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 05-02-2025
Indicate Company website link for updated RPT policy of the Company https://www.artemishospitals.com/BackEndImages/downloads/Investorsdata/related-party-transaction-policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No such default



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 30,570.62 58,771.59
Other income 817.94 1,357.52
Total income 31,388.56 60,129.11
2 Expenses
(a) Cost of materials consumed 6,253.74 12,163.79
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 4,299.74 8,475.67
(e) Finance costs 738.79 1,380.99
(f) Depreciation, depletion and amortisation expense 1,412.18 2,647.46
(f) Other Expenses
1 Other Expenses 14,607.83 27,173.94
Total other expenses 14,607.83 27,173.94
Total expenses 27,312.28 51,841.85
3 Total profit before exceptional items and tax 4,076.28 8,287.26
4 Exceptional items 0.00 0.00
5 Total profit before tax 4,076.28 8,287.26
6 Tax expense
7 Current tax 867.98 1,872.02
8 Deferred tax 112.99 214.82
9 Total tax expenses 980.97 2,086.84
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 3,095.31 6,200.42
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 3,095.31 6,200.42
17 Other comprehensive income net of taxes (39.04) (42.29)
18 Total Comprehensive Income for the period 3,056.27 6,158.13
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,583.06 1,583.06
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.96 3.92
Diluted earnings (loss) per share from continuing operations 1.96 3.92
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.96 3.92
Diluted earnings (loss) per share from continuing and discontinued operations 1.96 3.92
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) The value of Earning per share for the quarter/half year is not annualised. Notes: 1. The above unaudited standalone financial results for the quarter and six months ended September 30, 2026 (the financial results) have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the Company at their respective meetings held on October 30, 2026. The Statutory Auditors, T R Chadha & Co LLP, have carried out a limited review of these financial results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) and have issued an unmodified conclusion. 2. The above financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS)34 Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India, and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). Please refer remaining notes from unaudited financial results filed in PDF format.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 76,719.59
Capital work-in-progress 6,127.78
Investment property
Goodwill 4,162.07
Other intangible assets 8,566.80
Intangible assets under development 118.65
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 1,501.50
Trade receivables, non-current
Loans, non-current 99.70
Other non-current financial assets
1 Other financial assets 488.78
Total of other non-current financial assets 488.78
Total non-current financial assets 2,089.98
Deferred tax assets (net)
Other non-current assets
1 Non-current tax assets (net) 598.78
2 Other non-current assets 14,046.95
Total of other non-current assets 14,645.73
Total non-current assets 1,12,430.60
2 Current assets
Inventories 1,659.28
Current financial asset
Current investments 0.00
Trade receivables, current 15,033.28
Cash and cash equivalents 1,828.16
Bank balance other than cash and cash equivalents 24,800.97
Loans, current 1,337.03
Other current financial assets
Total of other current financial assets 1,531.52
Total current financial assets 44,530.96
Current tax assets (net)
Other current assets
1 Other current assets 628.16
Total of other current assets 628.16
Total current assets 46,818.40
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 1,59,249.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,583.06
Other equity 97,729.46
Total equity attributable to owners of parent 99,312.52
Non controlling interest
Total equity 99,312.52
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 20,217.93
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease Liabilities 7,826.96
Total of other non-current financial liabilities 7,826.96
Total non-current financial liabilities 28,044.89
Provisions, non-current 1,517.77
Deferred tax liabilities (net) 4,475.71
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 34,038.37
Current liabilities
Current financial liabilities
Borrowings, current 3,928.86
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,910.62
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 9,869.17
Total Trade payable 11,779.79
Other current financial liabilities
1 Lease Liabilities 358.89
2 Other financial liabilities 3,855.11
Total of other current financial liabilities 4,214.00
Total current financial liabilities 19,922.65
Other current liabilities 3,131.59
1 Other current liabilities 3,131.59
Total of other current liabilities 3,131.59
Provisions, current 2,049.09
Current tax liabilities (Net) 794.78
Deferred government grants, Current
Total current liabilities 25,898.11
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 59,936.48
Total equity and liabilites 1,59,249.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement gain/(loss) of defined employee benefit plans (68.02) (88.21)
2 Deferred Tax adjustment on revaluation that will not be reclassified to profit or loss 11.86 23.72
Total Amount of items that will not be reclassified to profit and loss (56.16) (64.49)
2 Income tax relating to items that will not be reclassified to profit or loss (17.12) (22.20)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (39.04) (42.29)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 8,287.26
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1,380.99
Adjustments for decrease (increase) in inventories (357.95)
Adjustments for decrease (increase) in trade receivables, current (4,001.80)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (111.63)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (55.24)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 2,218.92
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 1,223.87
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 2,647.46
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 101.61
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 1,293.06
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (7.63)
Adjustments for dividend income 0.00
Adjustments for interest income 1,001.78
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) (38.20)
Other adjustments for non-cash items 121.49
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 3,413.17
Net cash flows from (used in) operations 11,700.43
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 580.52
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 11,119.91
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 23.82
Purchase of property, plant and equipment 11,235.40
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 713.04
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 1,177.23
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (1,327.47)
Net cash flows from (used in) investing activities (12,074.86)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 3,298.00
Repayments of borrowings 1,720.87
Payments of lease liabilities 291.09
Dividends paid 665.21
Interest paid 1,141.38
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (520.55)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (1,475.50)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (1,475.50)
Cash and cash equivalents cash flow statement at beginning of period 3,303.66
Cash and cash equivalents cash flow statement at end of period 1,828.16





Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 16-05-2024
Amount Raised 33,000.00
Report filed for Quarter ended 30-09-2026
Monitoring Agency Applicable
Monitoring Agency Name, if applicable Care Ratings Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation Not Applicable
Comments of the Audit Committee after review No Comments
Comments of the auditors, if any No Comments
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 To support acquisition, expansion and capital expenditure requirements of the Company and its subsidiaries (including, by way of investment in its subsidiaries) Not Applicable 32,000.00 0.00 15,643.00 0.00 (a) During the quarter ended September 30, 2026, the Company utilized Rs. 10.36 crore from the issue proceeds for its capex requirements, comprising Rs. 9.97 crore towards procurement of medical equipment and TDR certificates for Artemis Gurgaon and Raipur Hospital and Rs. 0.39 crore towards construction of VIMHANS Hospital, Delhi. (b) Pending utilization of funds as per Objects of the Issue, the Company has temporarily parked unutilized amount in Fixed Deposits Receipt with Scheduled Banks.
2 Other general corporate purposes Not Applicable 1,000.00 0.00 827.00 0.00 (a) No amount was utilized during the quarter ended September 30, 2026. (b) Pending utilization of funds as per Objects of the Issue, the Company has temporarily parked unutilized amount in Fixed Deposits Receipt with Scheduled Banks.


Signatory Details

Name of signatory Sanjiv Kumar Kothari
Designation of person Chief Financial Officer
Place Gurugram
Date 30-10-2026




Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Artemis Medicare Services Limited Apollo Tyres Global Business Services Limited Enterprises owned or significantly influenced by Promoter or Promoter Group or Director and key management personnel or their relatives Any other transaction Lease Rent paid 2.34 NA 0.41 0.00 0.00
2 Artemis Medicare Services Limited Apollo Green Energy Limited Enterprises owned or significantly influenced by Promoter or Promoter Group or Director and key management personnel or their relatives Sale of goods or services 40.00 NA 1.85 31.10 32.95
3 Artemis Medicare Services Limited Premedium Pharmaceuticals Private Limited Enterprises owned or significantly influenced by Promoter or Promoter Group or Director and key management personnel or their relatives Purchase of goods or services 600.00 NA 306.05 60.21 60.18
4 Artemis Medicare Services Limited Artemis Health Sciences Foundation Enterprises owned or significantly influenced by Promoter or Promoter Group or Director and key management personnel or their relatives Any other transaction Medical equipment hire charges paid 12.00 NA 6.00 0.00 0.00
5 Artemis Medicare Services Limited Artemis Education & Research Foundation Enterprises owned or significantly influenced by Promoter or Promoter Group or Director and key management personnel or their relatives Any other transaction Medical equipment Usages Charges received 15.00 NA 0.04 0.00 0.00
6 Artemis Medicare Services Limited Apollo Tyres Limited Enterprises owned or significantly influenced by Promoter or Promoter Group or Director and key management personnel or their relatives Sale of goods or services 400.00 NA 211.61 91.51 212.36
7 Artemis Medicare Services Limited Artemis Cardiac Care Private Limited Subsidiary Purchase of fixed assets 500.00 NA 2.06 0.00 0.00
8 Artemis Medicare Services Limited Artemis Cardiac Care Private Limited Subsidiary Any other transaction Corporate Guarantee fee received 20.00 NA 2.96 7.12 9.09
9 Artemis Medicare Services Limited Artemis Cardiac Care Private Limited Subsidiary Any other transaction Sale of Pharmaceuticals/Medical supplies/Consumables & Medical services 20.00 NA 8.30 7.66 15.26
10 Artemis Medicare Services Limited Artemis Cardiac Care Private Limited Subsidiary Any other transaction Artemis Brand Usage Charges received 20.00 NA 3.82 4.00 6.30
11 Artemis Medicare Services Limited Artemis Cardiac Care Private Limited Subsidiary Any other transaction Corporate Guarantee Issued NA 0.00 1,000.00 1,000.00
12 Artemis Medicare Services Limited Artemis Cardiac Care Private Limited Subsidiary Investment NA 0.00 1,501.50 1,501.50
13 Artemis Cardiac Care Private Limited Philips Medical Systems Nederland B.V. Entity having significant influence over the subsidiary company Investment NA 0.00 808.50 808.50 Textual Information(1)
14 Artemis Medicare Services Limited Onkar Kanwar Promoter and Director Any other transaction Director Sitting Fee/Commission 18.00 NA 18.00 0.00 0.00 Textual Information(2)
15 Artemis Medicare Services Limited Neeraj Singh Kanwar Director Any other transaction Director Sitting Fee/Commission 18.60 NA 18.60 0.00 0.00 Textual Information(3)
16 Artemis Medicare Services Limited Shalini Kanwar Chand Director Any other transaction Director Sitting Fee/Commission 18.60 NA 18.60 0.00 0.00 Textual Information(4)
17 Artemis Medicare Services Limited Devlina Chakravarty Managing Director Any other transaction Salary Advance/Loan Given as per company's policy 500.00 NA 500.00 0.00 500.00
18 Artemis Medicare Services Limited Poonam Makkar Key Managerial Personnel Any other transaction Salary Advance/Loan Given as per company's policy NA 0.00 2.92 0.00
19 Artemis Medicare Services Limited Devarchana Rana Relative of Director / KMP Purchase of goods or services 15.00 NA 6.42 0.00 0.00
20 Artemis Medicare Services Limited Anil Khetarpal Director of Subsidiary Company Purchase of goods or services 25.00 NA 5.85 0.00 0.00 Textual Information(5)
21 Artemis Medicare Services Limited Dhananjay Kumar Jhamb Director of Subsidiary Company Purchase of goods or services 250.00 NA 100.00 0.00 0.00
22 Artemis Cardiac Care Private Limited Apollo Tyres Global Business Services Limited Enterprises owned or significantly influenced by Promoter or Promoter Group or Director and key management personnel of Holding Company or their relatives Any other transaction Lease Rent Expense No approval of Audit Committee required 0.41 0.00 0.00
23 Artemis Cardiac Care Private Limited Apollo Supply Chain Private Limited Enterprises owned or significantly influenced by Promoter or Promoter Group or Director and key management personnel of Holding Company or their relatives Any other transaction Lease Rent Expense No approval of Audit Committee required 0.48 0.15 0.00
24 Artemis Medicare Services Limited Artemis Health Sciences Foundation Enterprises owned or significantly influenced by Promoter or Promoter Group or Director and key management personnel or their relatives Sale of goods or services 50.00 NA 0.00 0.02 0.02
Total value of transaction during the reporting period 1,211.46



Text Block

Textual Information(1) Investment by Philips Medical Systems Nederland B.V. in Artemis Cardiac Care Private Limited
Textual Information(2) Commission for FY26 was paid in quarter ended September 30, 2026
Textual Information(3) Commission for FY26 was paid in quarter ended September 30, 2026
Textual Information(4) Commission for FY26 was paid in quarter ended September 30, 2026
Textual Information(5) Ceased to be director of the subsidiary w.e.f. close of business hours on April 30, 2026